Natera vs. Tempus AI: Which Blood Test Pioneer Has the Better Stock Buy for 2027?

Source The Motley Fool

Key Points

  • Natera dominates the molecular diagnostics market with high revenue growth and positive free cash flow.

  • Tempus AI leverages a massive multimodal data library and artificial intelligence to drive precision medicine.

  • Which high-growth healthcare technology stock is the better choice for your long-term portfolio?

  • Motley Fool Issues Rare "Total Conviction" Buy Alert ›

Can modern diagnostics and artificial intelligence reshape the future of medicine? Investors looking for growth must choose between Natera Inc. (NASDAQ:NTRA) and Tempus AI (NASDAQ:TEM) as they target the next era of healthcare.

Natera focuses on liquid biopsy and genetic testing to provide insights into oncology and reproductive health. Tempus AI applies large-scale data analysis and machine learning to help physicians personalize patient treatments. Both companies sit at the intersection of biology and technology, but their financial structures and risk profiles differ significantly for those looking toward 2027.

The case for Natera

Natera is a global leader in molecular diagnostics, specializing in cell-free DNA testing for oncology, women's health, and organ health. It serves a global network of partners, relying on Illumina Inc. (NASDAQ:ILMN) for sequencers and Amazon.com Inc. (NASDAQ:AMZN) for data hosting to manage its genomic data. The company is actively expanding its reach through collaborations, such as its partnership for minimal residual disease testing in China, while targeting a large total addressable market among healthcare stocks focusing on precision diagnostics.

In the 12 months ended Sept. 30, 2026, revenue reached about $2.9 billion. This figure represented growth of approximately 37.4% compared to the previous twelve-month period, driven by strong adoption across its testing platforms. Despite the strong growth, the company reported a net loss of about $164.7 million as it continues to invest in scaling its laboratory operations and research pipeline.

As of its December 2025 balance sheet, the current ratio stands at roughly 3.4x, which measures a company's ability to pay short-term obligations with liquid assets. Its debt-to-equity ratio, which compares total debt to shareholder equity, is approximately 0.1x, suggesting a relatively low level of leverage. In the fiscal year ended Dec. 31, 2025, free cash flow was nearly $109.1 million, but stock-based compensation represented roughly 164.6% of operating cash flow, meaning reported cash generation is heavily inflated by this non-cash add-back.

The case for Tempus AI

Tempus AI operates a sophisticated platform that integrates clinical and molecular data to help physicians personalize patient care across oncology and other therapeutic areas. It works extensively with pharmaceutical companies like AstraZeneca (NYSE:AZN) and biotechnology firms to support drug development and clinical trials. The company also utilizes Google Cloud from Alphabet Inc (nasdaq:goog) to maintain its vast multimodal data library, which serves as the backbone for its AI-driven diagnostic tools.

In the 12 months ended Sept. 30, 2026, revenue reached about $1.5 billion. The company achieved revenue growth of roughly 36.6% over the preceding year, highlighting the rapid expansion of its data-as-a-service and clinical testing businesses. During this same time frame, the company recorded a net loss of approximately $189.3 million, reflecting the high costs associated with developing and maintaining its proprietary technology platform.

As of its December 2025 balance sheet, the current ratio is roughly 3.1x. Its debt-to-equity ratio is approximately 2.7x, which compares total debt to the value owned by shareholders. In the fiscal year ended Dec. 31, 2025, free cash flow was negative at around $245.4 million, which represents the cash a business generates after accounting for the money spent to maintain or expand its asset base.

Risk profile comparison

Natera faces risks from its heavy reliance on a small number of core tests, including Signatera and Panorama. It also navigates intense competition in the molecular testing market from rivals like Guardant Health (NASDAQ:GH). Legal challenges and patent litigation with other diagnostic firms remain a persistent concern for the business as it seeks to protect its proprietary technology.

Tempus AI is subject to risks related to the accuracy and bias of its artificial intelligence models in clinical settings. The company also deals with high revenue concentration within its oncology product line. Furthermore, federal regulators have issued inquiries regarding its Medicare billing practices, which could lead to future legal or financial complications that impact shareholder value.

Valuation comparison

Based on the Forward P/E and P/S ratio, Tempus AI appears to be the more affordable option, while Natera trades at a premium.

MetricNateraTempus AI
Forward P/E273.0x118.4x
P/S ratio14.4x7.6x

Valuation metrics include those sourced from Financial Modeling Prep (FMP) and may differ from those of other data providers.

Which stock would I buy for 2027?

Natera built its early reputation on Panorama, a noninvasive prenatal blood test that screens for a broad range of fetal conditions. Widely adopted across the U.S., Panorama recently received an upgrade designed to close its primary clinical limitation: detecting chromosomal abnormalities even when levels of placental DNA fragments in maternal blood are too low for the prior version to read. Meanwhile, the company's broader DNA-testing momentum is accelerating, supported by roughly 70 active clinical trials focused on earlier cancer detection, identifying additional tumor types, and pinpointing patients who need expedited treatment.

Today, Natera's flagship revenue driver is Signatera, which generates roughly half of total sales. Both Medicare and commercial insurers have been expanding coverage and raising payouts for Signatera--including in breast and ovarian cancers--pushing average reimbursement per test up nearly 40% to almost $1,300 earlier this year. Adding further clinical validation, a U.S. regulatory committee granted Signatera a Category 1 recommendation for use in muscle-invasive bladder cancer this summer.

All that has the business seeing revenue growing at a fast clip, with 2026 expected to come in 30% higher than 2025 and 2027 rising another 23% to about $3.7 billion. While profitability isn't expected until fiscal 2028, the net losses are narrowing and free cash flow is rising.

Meanwhile, Tempus AI CEO Eric Lefkofsky said late this summer that he expects top-line growth of at least 25% annually over the coming years. Tempus AI's data unit has been a standout driver, closing $200 million in deals this summer with partners including Daiichi Sankyo, LevelSet Bio, and Insight Pharmaceuticals, up from over $100 million in each of the prior two quarters. Tempus argues that combining a massive data catalog with continuously learning AI gives its genomic testing an edge over traditional laboratory diagnostics. Raising per-test payouts is another top goal that is gaining traction: Q1 FY2026 revenue per test rose $130 from the prior-year period to $1,850. Following May approval of its tumor-only xT CDx test, analysts see room for meaningful revenue gains through higher pricing across Tempus's diagnostic suite--potentially reaching $400 million next year contingent on approval of a related xF test.

For fiscal 2026, sales should come in around $1.6 billion, a 26% rise from 2025, with a narrower net loss of about $187 million.

Both blood test pioneer stocks come at high premiums, as shown by their forward P/E ratios, but the businesses appear to justify the high hopes. Natrera's revolutionary cell-free DNA (cfDNA) test continues to show promise in detecting more cancers and becoming a standard of care in multiple situations. Sometimes the best stocks are the ones worth paying up for.

Should you buy stock in Natera right now?

Before you buy stock in Natera, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Natera wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $322,605!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $927,581!*

Now, it’s worth noting Stock Advisor’s total average return is 790% — a market-crushing outperformance compared to 202% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 19, 2026.

Brendan Coffey has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon, AstraZeneca Plc, Illumina, Natera, and Tempus AI. The Motley Fool recommends Guardant Health. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Gold Price Forecast: XAU/USD regains ground below $3,700, outlook remains fragileGold price (XAU/USD) attracts some bids after hitting a fresh yearly low at $3,693.50 on Thursday. In the European trade, the Gold price is 0.42% higher to near $3,740.
Author  FXStreet
11 hours ago
Gold price (XAU/USD) attracts some bids after hitting a fresh yearly low at $3,693.50 on Thursday. In the European trade, the Gold price is 0.42% higher to near $3,740.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 19, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 19, 2026. Read on for the details.
Author  Mitrade
16 hours ago
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 19, 2026. Read on for the details.
placeholder
Australian Dollar falls below 0.6700 as Unemployment Rate jumps to the highest level in five yearsThe AUD/USD pair tumbles to its lowest since January around 0.6695 during the early Asian session on Thursday. The Australian Dollar (AUD) faces some selling pressure against the US Dollar (USD) following weaker-than-expected Australian employment data.
Author  FXStreet
18 hours ago
The AUD/USD pair tumbles to its lowest since January around 0.6695 during the early Asian session on Thursday. The Australian Dollar (AUD) faces some selling pressure against the US Dollar (USD) following weaker-than-expected Australian employment data.
placeholder
US Dollar Index Price Forecast: DXY could target 104.00 as bulls await FOMC MinutesThe US Dollar Index (DXY), which tracks the Greenback against a basket of currencies, regains positive traction following the previous day's brief pause, retesting its highest level since April 2025 during the first half of the European session on Wednesday.
Author  FXStreet
Yesterday 10: 14
The US Dollar Index (DXY), which tracks the Greenback against a basket of currencies, regains positive traction following the previous day's brief pause, retesting its highest level since April 2025 during the first half of the European session on Wednesday.
placeholder
Gold Hits Near 1.5-Year Low Below $3,800 as Bears Threaten Drop to $3,500Gold prices broke below the $3,800 threshold to hit a new low since September 2025, warranting heightened vigilance over downside risk toward $3,500.On November 18, international spot gol
Author  TradingKey
Yesterday 08: 35
Gold prices broke below the $3,800 threshold to hit a new low since September 2025, warranting heightened vigilance over downside risk toward $3,500.On November 18, international spot gol
goTop
quote